A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl (Q44645852)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 1, 2004

Language	Label	Description	Also known as
English	A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl	scientific article published on January 1, 2004

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl (English)

1 reference

Europe PubMed Central

5 December 2017

1 reference

based on heuristic

inferred from title

1 reference

10.1038/SJ.LEU.2403203

https://api.crossref.org/works/10.1038/SJ.LEU.2403203

29 March 2024

author name string

S. Mishra

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603339

29 March 2024

B. Zhang

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603339

29 March 2024

J. Groffen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603339

29 March 2024

N. Heisterkamp

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603339

29 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14603339

29 March 2024

publication date

1 January 2004

1 reference

Europe PubMed Central

5 December 2017

full work available at URL

https://www.nature.com/articles/2403203.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603339

29 March 2024

https://www.nature.com/articles/2403203.pdf

Portable Document Format

1 reference

10.1038/SJ.LEU.2403203

https://api.crossref.org/works/10.1038/SJ.LEU.2403203

29 March 2024

https://www.nature.com/articles/2403203

1 reference

10.1038/SJ.LEU.2403203

https://api.crossref.org/works/10.1038/SJ.LEU.2403203

29 March 2024

1 reference

Europe PubMed Central

5 December 2017

18

1 reference

Europe PubMed Central

5 December 2017

1

1 reference

Europe PubMed Central

5 December 2017

23-28

1 reference

Europe PubMed Central

5 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403203

0 references

Chronic myelogenous leukemia: mechanisms underlying disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Farnesyltransferase inhibitors: potential role in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Farnesyl transferase inhibitors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Ras processing as a therapeutic target in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Farnesyl transferase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Ras family signaling: therapeutic targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Genetic analysis of chemoresistance in primary murine lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

21 January 2018

Abl: mechanisms of regulation and activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403203

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403203

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44645852&oldid=2116550256"